Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Richeldi

Showing results (141-150 of 356) with videos related to

Pageof 36
Sort By:
Therapeutic Advances in Respiratory Disease|September 30, 2021
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategiesGiorgio Walter Canonica, Pierluigi Paggiaro, Francesco Blasi, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|December 21, 2023
Images in Sarcoidosis: new section of our JournalRobert P Baughman, Antonella Caminati, Claudia Ravaglia, et al.
American Journal of Respiratory and Critical Care Medicine|July 17, 2012
Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trialsRoland M du Bois, Steven D Nathan, Luca Richeldi, et al.
Respiratory Research|November 2, 2024
Patient-centered care in pulmonary fibrosis: access, anticipate, and actDelian E Hofman, Tonia Magrì, Catharina C Moor, et al.
Advances in Therapy|August 9, 2020
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance DataJoseph A Lasky, Gerard J Criner, Howard M Lazarus, et al.
ERJ Open Research|May 3, 2019
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stageChristopher J Ryerson, Martin Kolb, Luca Richeldi, et al.
Pediatrics|January 4, 2007
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infectionLuca Richeldi, Katie Ewer, Monica Losi, et al.
Annals of Internal Medicine|May 6, 2004
Early diagnosis of subclinical multidrug-resistant tuberculosisLuca Richeldi, Katie Ewer, Monica Losi, et al.
Cells|June 2, 2021
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?Elia Bari, Ilaria Ferrarotti, Laura Saracino, et al.
Annals of the American Thoracic Society|March 25, 2021
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility StudyGiacomo Sgalla, Bruno Iovene, Teresa Bruni, et al.
Pageof 36

Showing results (141-150 of 356) with videos related to

Sort By:
Pageof 36
Therapeutic Advances in Respiratory Disease|September 30, 2021
Manifesto on the overuse of SABA in the management of asthma: new approaches and new strategiesGiorgio Walter Canonica, Pierluigi Paggiaro, Francesco Blasi, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|December 21, 2023
Images in Sarcoidosis: new section of our JournalRobert P Baughman, Antonella Caminati, Claudia Ravaglia, et al.
American Journal of Respiratory and Critical Care Medicine|July 17, 2012
Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trialsRoland M du Bois, Steven D Nathan, Luca Richeldi, et al.
Respiratory Research|November 2, 2024
Patient-centered care in pulmonary fibrosis: access, anticipate, and actDelian E Hofman, Tonia Magrì, Catharina C Moor, et al.
Advances in Therapy|August 9, 2020
Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis: Global Pharmacovigilance DataJoseph A Lasky, Gerard J Criner, Howard M Lazarus, et al.
ERJ Open Research|May 3, 2019
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stageChristopher J Ryerson, Martin Kolb, Luca Richeldi, et al.
Pediatrics|January 4, 2007
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infectionLuca Richeldi, Katie Ewer, Monica Losi, et al.
Annals of Internal Medicine|May 6, 2004
Early diagnosis of subclinical multidrug-resistant tuberculosisLuca Richeldi, Katie Ewer, Monica Losi, et al.
Cells|June 2, 2021
Mesenchymal Stromal Cell Secretome for Post-COVID-19 Pulmonary Fibrosis: A New Therapy to Treat the Long-Term Lung Sequelae?Elia Bari, Ilaria Ferrarotti, Laura Saracino, et al.
Annals of the American Thoracic Society|March 25, 2021
Telemedicine-enabled, Hotel-based Management of Patients with COVID-19: A Single-Center Feasibility StudyGiacomo Sgalla, Bruno Iovene, Teresa Bruni, et al.
Pageof 36